孕期使用核苷(酸)类药物预防乙型肝炎病毒母婴传播的效果和不良事件

• 作者: 周乙华 林晓倩 胡娅莉
• 来源期刊: 中国病毒病杂志
• 学科: 医学
• 关键词: 乙型肝炎病毒 核苷(酸)类药物 母婴传播 孕妇
• 年，卷（期）: 2015,（3）
• 所属期刊栏目: 专家论坛
• 页码范围: 161-166
• 页数: 6页
• 分类号: R512.6+2
• 语种: 中文

摘要

Mother-to-infant transmission of hepatitis B remains the main cause of chronic hepatitis B virus (HBV) infection in China.With the passive-active immunoprophylaxis,only ＜1 ％ infants born to HBV-infected mothers with negative HBeAg become chronically infected;however,approximately 10％ of the infants born to HBeAg-positive mothers are infected.The major risk factor of transmission is high maternal HBV DNA level or HBeAg positivity.Recently,it is shown that the use of nucleos(t)ide analogues (NAs) against HBV infection in pregnant women with positive HBeAg may reduce or eliminate the mother-to-infant transmission.However,the safety of these drugs is the major concern because using NAs during pregnancy appears to be associated with more adverse events for both pregnant women/mothers and their fetus/infants.Thus,it should be cautious to treat pregnant women with NAs for the prevention of mother-to infant transmission of hepatitis B.